WuXi Biologics Achieves ISO 13485 Certification, Signifying Strong Capabilities in Drug-Device Combination Product Development and Manufacturing

Company is among the first in China's drug-device combination products sector to obtain this certification, delivering superior solutions to global clients Zero non-conformities demonstrates company's robust quality management system SHANGHAI, April 14, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has successfully achieved ISO 13485:2016 Medical Device Quality Management System certification with zero non-conformities, becoming among the first in China's drug-device combination products sector to obtain this certification. The achievement highlights the company's robust quality system and strong compliance capabilities, reflecting a solid foundation for delivering safe, stable and reliable end-to-end services to clients worldwide.